Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Current drugs for osteoporosis primarily prevent bone loss, and there is a substantial need for treatments that could reduce fracture risk further. Rosen and colleagues describe recent insights into skeletal physiology that are providing the basis for novel therapeutics to promote bone formation, and discuss the regulatory and commercial challenges for these agents.
